Profile data is unavailable for this security.
About the company
Kangmei Pharmaceutical Co., Ltd is a China-based company, principally engaged in the manufacture and sales of pharmaceutical products. The Company's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera flower, among others. The Company is also engaged in the trading of Chinese herbal medicines, medical equipment and healthcare products related businesses. It also engages in the provision of real estate leasing and distribution services, among others. The Company mainly conducts its businesses within domestic markets.
- Revenue in CNY (TTM)5.21bn
- Net income in CNY255.55m
- Incorporated1997
- Employees4.41k
- LocationKangmei Pharmaceutical Co LtdTaike Road, Xiameilin, Futian DistrictSHENZHEN 518000ChinaCHN
- Phone+86 75 533187777
- Fax+86 75 586275777
- Websitehttp://www.kangmei.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.88bn | -422.97m | 23.78bn | 1.45k | -- | 3.79 | -- | 6.13 | -0.3269 | -0.3269 | 2.43 | 3.88 | 0.3774 | 0.5012 | 4.35 | 2,672,280.00 | -4.12 | 8.97 | -5.76 | 13.15 | 41.00 | 45.59 | -10.91 | 20.12 | 1.51 | -2.96 | 0.269 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Shanghai Junshi Biosciences Co Ltd | 1.79bn | -1.80bn | 25.55bn | 2.53k | -- | 4.78 | -- | 14.29 | -1.83 | -1.83 | 1.81 | 6.26 | 0.1593 | 0.8406 | 4.29 | 695,986.10 | -17.55 | -18.87 | -21.98 | -23.11 | 69.07 | 69.13 | -110.18 | -88.41 | 1.75 | -67.73 | 0.3065 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.35bn | 1.14bn | 27.09bn | 8.22k | 23.77 | 3.08 | -- | 2.90 | 0.7772 | 0.7772 | 6.34 | 5.99 | 0.4922 | 1.02 | 3.51 | 1,137,186.00 | 6.01 | 5.67 | 8.37 | 8.07 | 61.97 | 60.52 | 12.21 | 11.61 | 0.7919 | 6.25 | 0.4541 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Kangmei Pharmaceutical Co Ltd | 5.21bn | 255.55m | 27.59bn | 4.41k | 107.45 | 3.92 | -- | 5.29 | 0.0185 | 0.0185 | 0.3766 | 0.5079 | 0.3626 | 1.45 | 2.55 | 1,182,457.00 | 1.80 | -17.60 | 2.77 | -32.24 | 20.63 | -72.78 | 4.95 | -101.19 | 0.8398 | -- | 0.0346 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 8.92bn | 2.78bn | 27.84bn | 5.23k | 9.97 | 1.98 | -- | 3.12 | 3.03 | 3.03 | 9.71 | 15.27 | 0.5135 | 3.08 | 4.60 | 1,706,101.00 | 16.04 | 16.23 | 20.68 | 20.88 | 78.36 | 82.64 | 31.23 | 24.42 | 3.55 | -- | 0.1024 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Gan & Lee Pharmaceuticals | 2.95bn | 580.86m | 29.43bn | 4.48k | 50.10 | 2.63 | -- | 9.98 | 0.9773 | 0.9773 | 4.97 | 18.65 | 0.2558 | 0.8458 | 8.94 | 657,602.00 | 5.04 | 8.30 | 5.40 | 8.83 | 72.92 | 85.39 | 19.71 | 26.44 | 6.77 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Bluestar Adisseo Co | 14.95bn | 1.09bn | 29.45bn | 2.73k | 27.02 | 1.86 | -- | 1.97 | 0.4064 | 0.4064 | 5.57 | 5.90 | 0.6887 | 5.18 | 8.01 | 5,466,479.00 | 5.03 | 5.28 | 6.07 | 6.94 | 29.20 | 30.31 | 7.30 | 8.76 | 1.16 | 7.83 | 0.1105 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Xiamen Amoytop Biotech Co Ltd | 2.60bn | 740.69m | 31.46bn | 1.96k | 42.47 | 13.89 | -- | 12.12 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
Data as of Nov 01 2024. Currency figures normalised to Kangmei Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
4.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Minmetals International Trust Co.,Ltd.as of 30 Jun 2023 | 231.90m | 1.70% |
| Guangdong Finance Trust Co., Ltd.as of 30 Jun 2023 | 181.82m | 1.34% |
| Chang'An International Trust Co., Ltd.as of 30 Jun 2023 | 148.00m | 1.09% |
| Mellon Investments Corp.as of 03 Oct 2024 | 233.93k | 0.00% |
| Amundi Asset Management SA (Investment Management)as of 01 Oct 2024 | 33.05k | 0.00% |
| UBS Asset Management Switzerland AGas of 28 Jun 2024 | 32.92k | 0.00% |
| F�rsta AP-fondenas of 30 Jun 2024 | 17.04k | 0.00% |
| UBS Asset Management (UK) Ltd.as of 28 Jun 2024 | 7.78k | 0.00% |
| DWS Investments (UK) Ltd.as of 03 Oct 2024 | 7.48k | 0.00% |
| Danske Bank A/S (Investment Management)as of 30 Sep 2024 | 7.35k | 0.00% |
More ▼
Data from 30 Jun 2023 - 23 Oct 2024Source: FactSet Research Systems Inc.
